Roche Holding AG (RHHVF)
| Market Cap | 348.31B +32.9% |
| Revenue (ttm) | 77.92B -0.8% |
| Net Income | 15.27B +30.9% |
| EPS | 18.98 +30.6% |
| Shares Out | n/a |
| PE Ratio | 22.80 |
| Forward PE | 17.06 |
| Dividend | 20.68 (4.64%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 312 |
| Open | 432.50 |
| Previous Close | 432.79 |
| Day's Range | 428.79 - 446.35 |
| 52-Week Range | 314.15 - 490.33 |
| Beta | 0.35 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 22, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsNews
NTHM's Index Rebalance Puts Thematic Rotation to Work
The latest rebalance of VettaFi's Thematic Rotation Quality Momentum Screened Index (TQRMS), tracked by the NBI Thematic Rotation ETF (NTHM:TSX), reshapes the portfolio around a new set of themes. GLP...
Roche signs drug-discovery deal with Atavistik Bio worth up to $2 billion
Drug developer Atavistik Bio said on Thursday it has signed a deal with Swiss drugmaker Roche potentially worth nearly $2 billion, including milestone payments, to develop oral treatments for cardio...
Roche’s Genentech reports ‘positive’ results from Phase 3 Imagination study
Genentech, a member of the Roche (RHHBY) Group, announced positive prespecified interim results from the ongoing Phase III Imagination study evaluating investigational sefaxersen in adults with primar...
Roche Drug Candidate Hits Target in Late-Stage Study for Autoimmune Disease
The company said it would share the study's interim data with health authorities with the aim of bringing the treatment to the market as soon as possible.
Positive interim data shows Roche's sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)
Basel, 23 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today positive prespecified interim results from the ongoing phase III IMAgINATION study evaluating investigational sefaxersen i...
Roche proposes former Takeda CEO for board seat
Roche on Wednesday said it was proposing Christoph Weber, the former CEO of Takeda Pharmaceuticals , for election to the Swiss company's board of directors at its AGM next March.
Positive Interim Data Shows Genentech's Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy (IgAN)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today positive prespecified interim results from the ongoing Phase III IMAg...
Change in Roche's Board of Directors
Roche announced today that the Board of Directors of Roche Holding Ltd has approved to propose Dr. Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to the Board of Directors at Roc...
European drugmakers call for faster trials, more spending to compete with US, China
European drugmakers called for beefed-up government spending on medicines, faster trials and IP protections as they sounded warnings on Tuesday that the continent's pharmaceutical industry risks los...
Roche's obesity drug boosts blood sugar control, drives 15.5% weight loss in mid-stage trial
Swiss drugmaker Roche said on Tuesday its experimental dual-acting obesity drug helped overweight or obese patients with type 2 diabetes lower blood sugar levels and lose an average 15.5% of their b...
Roche Stock (RHHBY) Rises as New Obesity Drug Promises to Slash Weight By a Fifth
Shares in pharmaceuticals group Roche ($RHHBY) put on around 2% in pre-market trading today after it said that its new expirimental obesity drug could help people shed nearly a fifth…
Roche Says Drug Helped Patients Reduce Blood-Sugar Levels, Weight in Trial
The results for enicepatide reinforce the company's ambitions to rapidly develop its portfolio of medicines for people with obesity, diabetes and cardiovascular disease.
Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today announced positive topline results from CT-388-104, a Phase II clini...
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity
Basel, 22 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) today announced positive topline results from CT-388-104, a Phase II clinical trial evaluating enicepatide (CT-388), an investigational, o...
Roche reports European Commission approves Susvimo for nAMD
Roche (RHHBY) announced that the European Commission has approved Susvimo for the treatment of neovascular age-related macular degeneration, or nAMD. “The European Commission approval of Susvimo now p...
European Commission approves Roche's Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)
Basel, 21 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Commission has approved Susvimo® (ranibizumab 100 mg/mL solution for injection) for the treatment of neo...
CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents
Roche (RHHBY) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of Ocrevus intravenous infusion for the treatment of pediatric ...
CHMP recommends EU approval of Roche's Ocrevus for children and adolescents with relapsing multiple sclerosis
Basel, 18 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the appro...
Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today celebrated the grand opening of the Roche Genentech Innovation Cente...
Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases
Basel, 17 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the grand opening of the Roche Genentech Innovation Center Boston, expanding Roche and Genentech's US research presence in...
Genentech reports CELESTIMO study meets primary endpoint
Genentech, a member of Roche (RHHBY), announced that the Phase III CELESTIMO study evaluating Lunsumio in combination with lenalidomide versus Rituxan plus lenalidomide in people with relapsed or refr...
Roche's Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study
Basel, 17 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the phase III CELESTIMO study evaluating Lunsumio® (mosunetuzumab) in combination with lenalidomide versus MabThera®/...
Genentech's Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the Phase III CELESTIMO study evaluating Lunsumio® (mosunetuzuma...
Roche announces MediLink’s phase III trial of Tam-Peli met primary endpoint
Roche (RHHBY) announced that its collaborator MediLink released interim results from the randomised phase III TAISHAN-302 trial evaluating Tam-Peli versus topotecan in Chinese patients with relapsed s...
Roche's collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
Basel, 13 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) today announced that its collaborator MediLink released interim results from the randomised phase III TAISHAN-302 trial evaluating Tam-Pel...